Patents by Inventor Kin Tso

Kin Tso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein kinase C inhibitors and uses thereof
    Patent number: 8394951
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 12, 2013
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Haoran Zhao, Rao Kolluri, Carlos Valdez, Kin Tso, Rajinder Singh, John Ramphal
  • Protein kinase C inhibitors and uses thereof
    Patent number: 8377924
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: February 19, 2013
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Rajinder Singh, Huí Li, Haoran Zhao, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu, Carlos Valdez, Jing Zhang, Emily Stauffer, Matthew Duncton, Salvador Alvarez
  • 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
    Patent number: 8334297
    Abstract: 2,4-Pyrimidinediamine compounds represented by formula (I), methods for preparing the same and methods for treating an inflammatory disorder and for inhibiting the production of IL-23 and/or stimulating the production of IL-10 using the same:
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 18, 2012
    Assignee: Rigel Pharmaceuticals Inc.
    Inventors: Hui Li, Esteban Masuda, Stephanie Yung, Taisei Kinoshita, Rongxian Ding, Rajinder Singh, Tarikere Gururaja, Donald G. Payan, Kin Tso
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 8299087
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: October 30, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Arvinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20120213795
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful.
    Type: Application
    Filed: May 3, 2012
    Publication date: August 23, 2012
    Inventors: Hui Li, Ankush Argade, Sambaiah Thota, David Carroll, Arvinder Sran, Robin Cooper, Rajinder Singh, Kin Tso, Somasekhar Bhamidipati
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 8193197
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: June 5, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Ankush Argade, Sambaiah Thota, David Carroll, Arvinder Sran, Robin Cooper, Rajinder Singh, Kin Tso, Somasekhar Bhamidipati
  • Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
    Publication number: 20110152518
    Abstract: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
    Type: Application
    Filed: November 22, 2010
    Publication date: June 23, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Hui Li, Ankush Argade, Rajinder Singh, Sambaiah Thota, David Carroll, Kin Tso, Vanessa Taylor, John McLaughlin, Vadim Markovtsov
  • PROTEIN KINASE C INHIBITORS AND USES THEREOF
    Publication number: 20110130415
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 1, 2010
    Publication date: June 2, 2011
    Inventors: Rajinder Singh, Kin Tso, Jing Zhang, Matthew Duncton, Salvador Alvarez, Rao Kolluri, John Ramphal, Sacha Holland
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 7915273
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: March 29, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20110027856
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: October 11, 2010
    Publication date: February 3, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Arvinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • Cycloalkyl substituted pyrimidinediamine compounds and their uses
    Patent number: 7868013
    Abstract: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: January 11, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Ankush Argade, Rajinder Singh, Sambaiah Thota, David Carroll, Kin Tso, Vanessa Taylor, John McLaughlin, Mark Markovtsov
  • Cycloalkyl substituted pyrimidinediamine compounds and their uses
    Patent number: 7858633
    Abstract: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: December 28, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Ankush Argade, Rajinder Singh, Sambaiah Thota, David Carroll, Kin Tso, Vanessa Taylor, John McLaughlin, Mark Markovtsov
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 7834024
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: November 16, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Avinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • PROTEIN KINASE C INHIBITORS AND USES THEREOF
    Publication number: 20100204208
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 21, 2010
    Publication date: August 12, 2010
    Inventors: Rajinder Singh, Hui Li, Haoran Zhao, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu, Carlos Valdez, Jing Zhang, Emily Stauffer, Matthew Duncton, Salvador Alvarez
  • PROTEIN KINASE C INHIBITORS AND USES THEREOF
    Publication number: 20100184755
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 13, 2010
    Publication date: July 22, 2010
    Inventors: Haoran Zhao, Rao Kolluri, Carlos Valdez, Kin Tso, Rajinder Singh, John Ramphal
  • METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS
    Publication number: 20100179165
    Abstract: Methods for treating an inflammatory disorder and for inhibiting the production of IL-23 using 2,4-pyrimidinediamine compounds represented by formula (I):
    Type: Application
    Filed: January 13, 2010
    Publication date: July 15, 2010
    Inventors: Tarikere Gururaja, Donald G. Payan, Kin Tso, Taisei Kinoshita, Rongxian Ding, Rajinder Singh, Stephanie Yung, Hui Li, Esteban Masuda
  • 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20100179164
    Abstract: 2,4-Pyrimidinediamine compounds represented by formula (I), methods for preparing the same and methods for treating an inflammatory disorder and for inhibiting the production of IL-23 and/or stimulating the production of IL-10 using the same:
    Type: Application
    Filed: January 13, 2010
    Publication date: July 15, 2010
    Inventors: Hui Li, Esteban Masuda, Stephanie Yung, Taisei Kinoshita, Rongxian Ding, Rajinder Singh, Tarikere Gururaja, Donald G. Payan, Kin Tso
  • Cycloalkyl substituted pyrimidinediamine compounds and their uses
    Patent number: 7754714
    Abstract: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: July 13, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Ankush Argade, Rajinder Singh, Sambaiah Thota, David Carroll, Kin Tso, Vanessa Taylor, John McLaughlin, Vadim M. V. Markovtsov
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20100152218
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS
    Publication number: 20100130486
    Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.
    Type: Application
    Filed: July 17, 2008
    Publication date: May 27, 2010
    Inventors: Rajinder Singh, Hui Li, Haoran Zhao, Donald Payan, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu